CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Notable Labs Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Notable Labs Ltd
320 Hatch Drive
Phone: (415) 851-2410p:415 851-2410 FOSTER CITY, CA  94404  United States Ticker: NTBLQNTBLQ
Filed for Bankruptcy on 10/13/2024
This company was Merged or Acquired on 10/16/2023.
Case #24-12336, filed in the U.S. Bankruptcy Court for the District of Delaware (Chapter 7)
This is a Subsidiary, click here for the Parent Company
Business Summary
Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Senior Vice President - Research and Operations EyalBreitbart 55 2/1/2022 1/1/2006
Senior Vice President - Business Operations ErezFeige 48 2/1/2022 1/1/2014
Senior Vice President - Clinical Development TamiRachmilewitz 51 2/1/2022 6/1/2018
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Notable Labs, Inc.
Notable Therapeutics, Inc.
NTBL
4 additional Business Names available in full report.

General Information
Number of Employees: 16 (As of 4/1/2024)
Outstanding Shares: 9,659,496 (As of 8/14/2024)
Shareholders: 138
Stock Exchange: OTC
Federal Tax Id: 512899766
Fax Number: +972 89935001


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024